NeuroPace develops the RNS System, a brain-responsive neuromodulation device for treating refractory epilepsy. The implanted system monitors brain activity and delivers targeted electrical stimulation when abnormal patterns are detected to reduce seizures. Clinicians receive data and analysis to guide therapy, and the company sells devices with ongoing support. The goal is to broaden adoption, expand to other neurological disorders, and grow revenue while improving seizure control and quality of life for patients.
Company Size
201-500
Company Stage
IPO
Headquarters
Mountain View, California
Founded
1999
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?